Literature DB >> 22350376

The impact of chemotherapy on cognitive outcomes in adults with primary brain tumors.

Lauren E Abrey1.   

Abstract

There is growing recognition that chemotherapy may have short and long term impact on cognitive function of cancer patients. However, the impact of chemotherapy on the cognition of adult patients with primary brain tumor has not been extensively studied. This article will review the evidence for both positive and negative impact of chemotherapy on cognitive function of adult brain tumor patients as well as potential confounding factors.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22350376     DOI： 10.1007/s11060-012-0807-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  47 in total

1.  Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma.

Authors:  L D McAllister; N D Doolittle; P E Guastadisegni; D F Kraemer; C A Lacy; J R Crossen; E A Neuwelt
Journal:  Neurosurgery       Date:  2000-01       Impact factor: 4.654

2.  Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.

Authors:  Jaime Gállego Pérez-Larraya; François Ducray; Olivier Chinot; Isabelle Catry-Thomas; Luc Taillandier; Jean-Sébastien Guillamo; Chantal Campello; Annick Monjour; Stéphanie Cartalat-Carel; Maryline Barrie; Aymeri Huchet; Patrick Beauchesne; Mona Matta; Karima Mokhtari; Marie-Laure Tanguy; Jérôme Honnorat; Jean-Yves Delattre
Journal:  J Clin Oncol       Date:  2011-06-27       Impact factor: 44.544

3.  Evidence for acute neurotoxicity after chemotherapy.

Authors:  Axel Petzold; Tjeerd Mondria; Jens Kuhle; Maria A Rocca; Jan Cornelissen; Peter te Boekhorst; Bob Lowenberg; Gavin Giovannoni; Massimo Filippi; Ludwig Kappos; Rogier Hintzen
Journal:  Ann Neurol       Date:  2010-12       Impact factor: 10.422

4.  Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced 'chemo-fog'.

Authors:  R B Raffa; R J Tallarida
Journal:  J Clin Pharm Ther       Date:  2010-06       Impact factor: 2.512

Review 5.  Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.

Authors:  M J van den Bent; J S Wefel; D Schiff; M J B Taphoorn; K Jaeckle; L Junck; T Armstrong; A Choucair; A D Waldman; T Gorlia; M Chamberlain; B G Baumert; M A Vogelbaum; D R Macdonald; D A Reardon; P Y Wen; S M Chang; A H Jacobs
Journal:  Lancet Oncol       Date:  2011-04-05       Impact factor: 41.316

6.  Prediction of neurocognitive outcome in adult brain tumor patients.

Authors:  Thomas A Kaleita; David K Wellisch; Timothy F Cloughesy; Judith M Ford; Donald Freeman; Thomas R Belin; Jeffrey Goldman
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

7.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

8.  Low-grade oligodendroglioma responds to chemotherapy.

Authors:  W P Mason; G S Krol; L M DeAngelis
Journal:  Neurology       Date:  1996-01       Impact factor: 9.910

9.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients.

Authors:  G Minniti; V De Sanctis; R Muni; F Filippone; A Bozzao; M Valeriani; M F Osti; U De Paula; G Lanzetta; V Tombolini; R Maurizi Enrici
Journal:  J Neurooncol       Date:  2008-02-05       Impact factor: 4.130

10.  Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings.

Authors:  Karen Hilverda; Ingeborg Bosma; Jan J Heimans; Tjeerd J Postma; W Peter Vandertop; Ben J Slotman; Jan Buter; Jaap C Reijneveld; Martin Klein
Journal:  J Neurooncol       Date:  2009-08-30       Impact factor: 4.130
View more
  9 in total

1.  Preservation of cognitive function in primary CNS lymphoma survivors a median of 12 years after enhanced chemotherapy delivery.

Authors:  Nancy D Doolittle; Edit Dósa; Rongwei Fu; Leslie L Muldoon; Leeza M Maron; Meredith A Lubow; Rose Marie Tyson; Cynthia A Lacy; Dale F Kraemer; Robert W Butler; Edward A Neuwelt
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

2.  Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma.

Authors:  Nancy D Doolittle; Agnieszka Korfel; Meredith A Lubow; Elisabeth Schorb; Uwe Schlegel; Sabine Rogowski; Rongwei Fu; Edit Dósa; Gerald Illerhaus; Dale F Kraemer; Leslie L Muldoon; Pasquale Calabrese; Nancy Hedrick; Rose Marie Tyson; Kristoph Jahnke; Leeza M Maron; Robert W Butler; Edward A Neuwelt
Journal:  Neurology       Date:  2013-05-17       Impact factor: 9.910

3.  Mitochondrial-associated impairments of temozolomide on neural stem/progenitor cells and hippocampal neurons.

Authors:  Naomi Lomeli; Kaijun Di; Diana C Pearre; Tzu-Feng Chung; Daniela A Bota
Journal:  Mitochondrion       Date:  2020-02-08       Impact factor: 4.160

Review 4.  Neurocognitive deficits following primary brain tumor treatment: systematic review of a decade of comparative studies.

Authors:  Amanda K Gehrke; Margaret C Baisley; Alexander L B Sonck; Samantha L Wronski; Michael Feuerstein
Journal:  J Neurooncol       Date:  2013-08-23       Impact factor: 4.130

5.  Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary utility in adult neuro-oncology.

Authors:  Ashlee R Loughan; Sarah E Braun; Autumn Lanoye
Journal:  Neurooncol Pract       Date:  2018-12-08

Review 6.  Sociocognitive Functioning and Psychosocial Burden in Patients with Brain Tumors.

Authors:  Milena Pertz; Uwe Schlegel; Patrizia Thoma
Journal:  Cancers (Basel)       Date:  2022-02-01       Impact factor: 6.639

7.  Mid-term treatment-related cognitive sequelae in glioma patients.

Authors:  Sabine Schlömer; Jörg Felsberg; Milena Pertz; Bettina Hentschel; Markus Löffler; Gabriele Schackert; Dietmar Krex; Tareq Juratli; Joerg Christian Tonn; Oliver Schnell; Hartmut Vatter; Matthias Simon; Manfred Westphal; Tobias Martens; Michael Sabel; Martin Bendszus; Nils Dörner; Klaus Fliessbach; Christian Hoppe; Guido Reifenberger; Michael Weller; Uwe Schlegel; For The German Glioma Network
Journal:  J Neurooncol       Date:  2022-07-07       Impact factor: 4.506

8.  Anaplastic astrocytoma and non-1p/19q co-deleted anaplastic oligoastrocytoma: long-term survival, employment, and performance status of survivors.

Authors:  Elena I Pentsova; Anne S Reiner; Katherine S Panageas; Lisa M DeAngelis
Journal:  Neurooncol Pract       Date:  2015-10-16

9.  Neurotoxicity of cancer chemotherapy.

Authors:  Miyoung Yang; Changjong Moon
Journal:  Neural Regen Res       Date:  2013-06-15       Impact factor: 5.135
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.